- Trial phase
- Phase 1/2a
- Time to market
- PSV359 is in early clinical development (Phase 1/2a). Even under an accelerated path, a potential approval is likely several years away, contingent on successful dose-finding, expansion cohorts, and pivotal trial design and execution.
- Why 3/10
- PSV359 is in early Phase 1/2a with no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next ~12 months. The Fast Track designation (October 2026) and Merck collaboration (September 2026) are past events. The drug is one of three clinical-stage programs at Perspective, and the company's value is not concentrated on PSV359 alone. Per the rubric, an early-stage drug with no near-term binary catalyst scores 3.
The next meaningful catalyst for PSV359 would be initial safety and efficacy data from the Phase 1/2a dose-escalation cohorts, but no specific readout date has been announced. Investors should also watch for updates on the Merck/Keytruda combination arm and any regulatory guidance on a potential pivotal path for the SFT Fast Track indication. The stock's dramatic decline from its 52-week high suggests the market has already priced in significant pipeline risk.
Price Chart
Executive Summary
PSV359 is an early-stage (Phase 1/2a) targeted alpha-particle radiotherapy from Perspective Therapeutics (CATX) that targets FAP-alpha, a protein on cancer-associated fibroblasts. It received FDA Fast Track designation in October 2026 for solitary fibrous tumors, a rare cancer, and Perspective has a clinical collaboration with Merck to test it in combination with Keytruda. However, the drug has no disclosed efficacy data yet, the stock has collapsed from $6.16 to $0.86 over the past year, and a major stockholder (Lantheus) has been selling shares. PSV359 is one of three clinical programs at a pre-revenue company burning $32M/quarter, with no near-term binary catalyst on the horizon.
How It Works
PSV359 is an investigational targeted radiotherapy. It consists of a molecule that binds to fibroblast activation protein alpha (FAP-alpha), a protein found on cells surrounding many solid tumors, attached to the radioactive isotope lead-212 (212Pb). When injected, the drug seeks out FAP-alpha on tumor-associated cells and delivers localized alpha radiation to kill cancer cells while largely sparing healthy tissue. This is called a targeted alpha-particle therapy.
Trial Status
PSV359 is being evaluated in an ongoing multi-center, open-label Phase 1/2a dose-finding and dose-expansion study in patients with advanced FAP-alpha positive solid tumors. The first patient was dosed in April 2025, and the second cohort began dosing in October 2025. The primary objective is safety and determination of the recommended Phase 2 dose. In September 2026, Perspective announced a clinical collaboration with Merck to evaluate PSV359 in combination with Keytruda (pembrolizumab) in non-small cell lung cancer and colorectal cancer patients. The FDA granted Fast Track Designation for PSV359 in October 2026 specifically for solitary fibrous tumors (SFTs), a rare cancer.
The Two-Sided Case
Upcoming Catalysts
- Phase 1/2a dose-escalation data updates (no specific date announced)
- Potential initiation of expansion cohorts in FAP-positive solid tumors
- Progress updates on the Merck/Keytruda combination arm
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Perspective Therapeutics, Inc. PRESS-RELEASE CATX ·Originating report